Abstract
Coronavirus Emerging evidence suggests that cytokine release syndrome (CRS), a systemic hyperinflammatory reaction, is a major cause of fatality in patients with severe coronavirus disease 2019 (COVID-19). CRS is observed in some other severe coronavirus infections, as well as in some cancer patients after receiving engineered T cell therapy. On the basis of this past experience, an emerging treatment for COVID-19 under investigation in the clinical setting is to antagonize key cytokine signaling pathways that drive CRS. In a Perspective, Moore and June discuss the current understanding of CRS immunopathology and the developments in repurposing drugs with a track record in treating CRS for treating patients with severe COVID-19. Science , this issue p. [473][1] [1]: /lookup/doi/10.1126/science.abb8925
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
